Form 8-K - Current report:
SEC Accession No. 0001213900-21-002841
Filing Date
2021-01-19
Accepted
2021-01-19 16:03:36
Documents
5
Period of Report
2021-01-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea133377-8k_wizepharma.htm 8-K 32713
2 DEED OF AMENDMENT, DATED JANUARY 18, 2021, OF THE BID IMPLEMENTATION AGREEMENT B ea133377ex2-1_wizepharma.htm EX-2.1 890022
3 FORM OF STOCK RESTRICTION AGREEMENT ea133377ex10-1_wizepharma.htm EX-10.1 65229
4 FORM OF CONTINGENT VALUE RIGHTS AGREEMENT ea133377ex10-2_wizepharma.htm EX-10.2 232084
5 GRAPHIC ex2-1_001.jpg GRAPHIC 2147
  Complete submission text file 0001213900-21-002841.txt   1224485
Mailing Address 24 HANAGAR ST HOD HASHARON L3 4527713
Business Address 24 HANAGAR ST HOD HASHARON L3 4527713 972 472 260 0536
Wize Pharma, Inc. (Filer) CIK: 0001218683 (see all company filings)

EIN.: 880445167 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-52545 | Film No.: 21535480
SIC: 2834 Pharmaceutical Preparations